Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an
initial diagnosis of prostate cancer and management options for localized, regional, and …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Prostate cancer remains one of the most commonly diagnosed malignancies worldwide.
Early diagnosis and curative treatment seem to improve survival in men with unfavourable …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Context Given the highly variable behavior and clinical course of prostate cancer (PCa) and
the multiple available treatment options, a personalized approach to oncologic risk …

Background A 17-gene biopsy-based reverse transcription polymerase chain reaction
assay, which provides a Genomic Prostate Score (GPS—scale 0–100), has been validated …